Rituximab for Refractory Wegener's. To evaluate the efficacy and safety of rituximab for remission induction in refractory Wegener's. Granulomatose de Wegener. Learn about Wegener's granulomatosis also known as granulomatosis with polyangiitis (GPA) causes, symptoms, and treatment. Granulomatosis with polyangiitis (GPA), previously known as Wegener's granulomatosis (WG), is a systemic disorder that involves both granulomatosis and polyangiitis.
Granulomatosis with Polyangiitis (Wegener Granulomatosis): Practice Essentials, Background, Etiology. Fauci AS, Haynes BS, Katz P, Wolff SM.
Granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis, is a rare multisystem autoimmune disease of unknown etiology. Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
Wegener's granulomatosis: prospective clinical and therapeutic experience with 8. Manganelli P, Fietta P, Carotti M, Pesci A, Salaffi F. Respiratory system involvement in systemic vasculitis.
Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 1. Neurological involvement in Wegener's granulomatosis. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Jayne D, Rasmussen N, Andrassey K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic antibodies.
Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). Falk RJ, Gross WL, Guillevin L, et al.
Granulomatosis with polyangiitis (Wegener. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1. Wegener's granulomatosis. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.
Limited versus severe Wegener's granulomatosis: baseline patient data on patients in the Wegener's granulomatosis etanercept trial. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's Granulomatosis.
Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study.
Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's Granulomatosis. Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ.
Pulmonary- renal syndrome in a newborn with placental transmission of ANCAs. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis.
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA- associated renal vasculitis. Pathogenesis of PR3- ANCA associated vasculitis. Falk RJ, Terrell RS, Charles LA, Jennett C. Anti- neutrophil cytoplasmic autoantibodies induce neutrophils todegranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA.
Pathophysiology of ANCA- associated small vessel vasculitis. Xiao H, Heeringa P, Liu Z, et al. The role of neutrophils in the induction of glomerulonephritis by anti- myeloperoxidase antibodies. Kallenberg CGM, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA- associated vasculitis.
Nat Clin Pract Rheumatol. Moosig F, Lamprecht P, Gross WL. Wegener's Granulomatosis: the current view. Clin Rev Allergy Immunol. Spagnolo P, Richeldi L, Du. Bois RM. Environmental triggers and susceptibility factors in idiopathic granulomatous diseases.
Semin Respir Crit Care Med. Carr EJ, Niederer HA, Williams J, et al. Confirmation of the genetic association of CTLA4 and PTPN2. ANCA- associated vasculitis. Jagiello P, Aries P, Arning L, et al. The PTPN2. 2 6. 20.
W allele is a risk factor for Wegener's granulomatosis. Heckmann M, Holle JU, Arning L, et al. The Wegener's granulomatosis quantitative trait locus on chromosome 6p. SNP genotyping. Pendergraft WF 3rd, Preston GA, Shah RR, et al. Autoimmunity is triggered by c. PR- 3(1. 05- 2. 01), a protein complementary to human autoantigen proteinase- 3.
Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci- immune focal necrotizing glomerulonephritis.
Hogan SL, Cooper GS, Savitz DA, et al. Association of silica exposure with anti- neutrophil cytoplasmic autoantibody small- vessel vasculitis: a population- based, case- control study. Clin J Am Soc Nephrol. Watts RA, Lane SE, Koldingsnes W, et al. Epidemiology of vasculitis in Europe. Lane SE, Watts R, Scott DGI.
Epidemiology of systemic vasculitis. Mukhtyar C, Flossmann O, Hellmich B, et al.
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Haroun MK, Stone JH, Nair R, Racusen L, Hellmann DB, Eustace JA. Correlation of percentage of normal glomeruli with renal outcome in Wegener's granulomatosis. September- December 2. Hauer HA, Bajema IM, Van Houwelingen HC, et al. Determinants of outcome in ANCA- associated glomerulonephritis: a prospective clinico- histopathological analysis of 9. Renaudineau Y, Le Meur Y.
Renal involvement in Wegener's Granulomatosis. Clinic Rev Allerg Immunol. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody- associated vasculitis: A meta- analysis. Arthritis Care Res (Hoboken). Mortality in systemic vasculitis: a systematic review. September- October 2.
Seo P, Min Y- I, Holbrook JT, et al. Damage caused by Wegener's Granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L. Incidence and predictors of urotoxic adverse events in cyclophosphamide- treated patients with systemic necrotizing vasculitides. Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody- associated vasculitis: follow- up data from European Vasculitis Study Group clinical trials.
Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Florian A, Slavich M, Blockmans D, Dymarkowski S, Bogaert J. Cardiac involvement in granulomatosis with polyangiitis (Wegener granulomatosis).
Mc. Geoch L, Carette S, Cuthbertson D, Hoffman GS, Khalidi N, Koening CL, et al. Cardiac Involvement in Granulomatosis with Polyangiitis. Hazebroek MR, Kemna MJ, Schalla S, Sanders- van Wijk S, Gerretsen SC, Dennert R, et al. Prevalence and prognostic relevance of cardiac involvement in ANCA- associated vasculitis: Eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Al- Hakeem DA, Fedele S, Carlos R, Porter S. Extranodal NK/T- cell lymphoma, nasal type. Frankel SK, Cosgrove GP, Fischer A.
Update in the diagnosis and management of pulmonary vasculitis. Rottem M, Fauci AS, Hallahan CW, Kerr GS, Lebovics R, Leavitt RY, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. Polychronopoulos VS, Prakash UBS, Golbin JM, Edell ES, Specks U. Airway involvement in Wegener's Granulomatosis.
Hervier B, Durant C, Masseau A, Ponge T, Hamidou M, Mussini JM. Use of muscle biopsies for diagnosis of systemic vasculitides. Nunokawa T, Yokogawa N, Shimada K, Enatsu K, Sugii S. The use of muscle biopsy in the diagnosis of systemic vasculitis affecting small to medium- sized vessels: a prospective evaluation in Japan.
De. Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody- associated vasculitis: a randomized trial. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data- driven review. Clowse ME, Copland SC, Hsieh TC, Chow SC, Hoffman GS, Merkel PA, et al.
Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken). Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Garcia- Valladares I, Espinoza LR. Is rituximab superior to cyclophosphamide for ANCA- associated vasculitis for induction of remission, and with a better safety profile?
Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody- associated vasculitis. Tesfa D, Ajeganova S, H. Late- onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections. Mc. Gregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti- neutrophil cytoplasmic antibody disease.
Clin J Am Soc Nephrol. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small- vessel vasculitis.
Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti- GBM antibodies. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high- dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg- Strauss syndrome and renal limited vasculitis.
De. Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody- associated vasculitis. Rhee EP, Laliberte KA, Niles JL.